Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Challenging ageism in gynaecological cancers
Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours
Data show that mirvetuximab soravtansine-gynx improves outcomes regardless of HRD status
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
Atezolizumab added to chemotherapy and bevacizumab is effective regardless of PD-L1 status in untreated recurrent and metastatic cervical cancer
An analysis of the BEATcc trial showed that PD-L1 is not a robust biomarker for response to treatment
Relacorilant added to nab-paclitaxel prolongs progression-free survival in platinum-resistant ovarian cancer
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Experts recommend limiting germline genetic testing for breast cancer to seven genes
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families